RayzeBio, Inc.
RYZBDelisted Feb 26, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001825367
RayzeBio, Inc. was delisted on Feb 26, 2024; its insiders filed their last Form 4 on Feb 28, 2024; 107 institutions reported holding it in 13F filings for Q4 2023, worth $3.40B in total; superinvestors Viking Global Investors and HHLR Advisors (Hillhouse) held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 107
- Q4 2023, +39 vs. previous quarter
- 13F value
- $3.40B
- Reported value at the end of Q4 2023
- Superinvestors holding
- 2
- At the end of Q4 2023
Superinvestors holding RYZB, Q4 2023
2 superinvestors report holding RayzeBio, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
1.5%
RayzeBio, Inc.'s share of the portfolio
- Shares
- 6,642,700
- Value
- $413.0M
HHLR Advisors (Hillhouse)
Zhang Lei
1.3%
RayzeBio, Inc.'s share of the portfolio
- Shares
- 1,062,383
- Value
- $66.0M
Latest insider trades
Open-market purchases and sales by RayzeBio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2023 (view filing)5:00 PM ET | Sep 19 | 2 days | Viking Global Investors LP and 7 others10% Owner | PPurchase | +1.39M | $18.00 | +$25.0M | +391.6%1.74M after | 2 lotsDuplicate filing |
| Sep 21, 2023 (view filing)4:59 PM ET | Sep 19 | 2 days | Viking Global Investors LP and 7 others10% Owner | PPurchase | +1.39M | $18.00 | +$25.0M | +391.6%1.74M after | 2 lots |
| Sep 21, 2023 (view filing) | Sep 19 | 2 days | Katabi MahaDirector | PPurchase | +472.2K | $18.00 | +$8.50M | +64.0%1.21M after | 2 lots |
Top 10 13F holders, Q4 2023
The largest institutional positions in RayzeBio, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Viking Global Investors LPSuperinvestorViking Global Investors | 6,642,700 | $413.0M | 1.51% | 00.0% | Unchanged |
| venBio Partners LLC | 5,158,162 | $320.7M | 48.06% | 00.0% | Unchanged |
| Versant Venture Management, LLC | 5,158,161 | $320.7M | 82.47% | 00.0% | Unchanged |
| VR Adviser, LLC | 4,030,471 | $250.6M | 17.19% | +13,624+0.3% | Added |
| Wellington Management Group LLP | 3,504,409 | $215.9M | 0.04% | −371,777−9.6% | Reduced |
| Sofinnova Investments, Inc. | 2,419,528 | $150.4M | 8.43% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 2,365,213 | $147.0M | 2.95% | −257,696−9.8% | Reduced |
| Redmile Group, LLC | 1,857,706 | $115.5M | 4.13% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,845,948 | $114.8M | 17.85% | 00.0% | Unchanged |
| BlackRock Inc. | 1,368,838 | $85.1M | 0.00% | +1,358,838+13,588.4% | Added |